2.16.840.1.113883.5.1070/static-2012-07-24: Unterschied zwischen den Versionen
ADbot (Diskussion | Beiträge) (Automated TermBot page content) |
ADbot (Diskussion | Beiträge) (Automated TermBot page content) |
||
| (2 dazwischenliegende Versionen desselben Benutzers werden nicht angezeigt) | |||
| Zeile 9: | Zeile 9: | ||
| colspan=2 bgcolor="#F6F3EE"|''substanceAdminSubstitution'' | | colspan=2 bgcolor="#F6F3EE"|''substanceAdminSubstitution'' | ||
| bgcolor="#F6F3EE"|2.16.840.1.113883.5.1070 | | bgcolor="#F6F3EE"|2.16.840.1.113883.5.1070 | ||
| − | | bgcolor="#F6F3EE"|2012-07- | + | | bgcolor="#F6F3EE"|2012-07-24 |
| bgcolor="#F6F3EE"|definitiv | | bgcolor="#F6F3EE"|definitiv | ||
|- | |- | ||
| Zeile 17: | Zeile 17: | ||
| bgcolor="#ECE9E4" colspan="2"|'''Beschreibung''' | | bgcolor="#ECE9E4" colspan="2"|'''Beschreibung''' | ||
|- | |- | ||
| + | |- | ||
| + | |0-A | ||
| + | |_ActSubstanceAdminSubstitutionCode | ||
| + | |[[Datei:EN-US.png]] ActSubstanceAdminSubstitutionCode | ||
| + | | colspan="2" |<p>Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.</p> | ||
| + | |- | ||
| + | |1-S | ||
| + | |'''E''' | ||
| + | |[[Datei:EN-US.png]] equivalent | ||
| + | | colspan="2" |<p>Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.</p> | ||
| + | |- | ||
| + | |2-S | ||
| + | |'''EC''' | ||
| + | |[[Datei:EN-US.png]] equivalent composition | ||
| + | | colspan="2" |<p>Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril</p> | ||
| + | |- | ||
| + | |3-L | ||
| + | |'''BC''' | ||
| + | |[[Datei:EN-US.png]] brand composition | ||
| + | | colspan="2" |<p>Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven</p> | ||
| + | |- | ||
| + | |3-L | ||
| + | |'''G''' | ||
| + | |[[Datei:EN-US.png]] generic composition | ||
| + | | colspan="2" |<p>Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)</p> | ||
| + | |- | ||
| + | |2-S | ||
| + | |'''TE''' | ||
| + | |[[Datei:EN-US.png]] therapeutic alternative | ||
| + | | colspan="2" |<p>Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet</p> | ||
| + | |- | ||
| + | |3-L | ||
| + | |'''TB''' | ||
| + | |[[Datei:EN-US.png]] therapeutic brand | ||
| + | | colspan="2" |<p>Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics> Examples: Zantac for Tagamet</p> | ||
| + | |- | ||
| + | |3-L | ||
| + | |'''TG''' | ||
| + | |[[Datei:EN-US.png]] therapeutic generic | ||
| + | | colspan="2" |<p>Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands> Examples: Ranitidine for cimetidine</p> | ||
| + | |- | ||
| + | |1-L | ||
| + | |'''F''' | ||
| + | |[[Datei:EN-US.png]] formulary | ||
| + | | colspan="2" |<p>Description: This substitution was performed or is permitted based on formulary guidelines.</p> | ||
| + | |- | ||
| + | |1-L | ||
| + | |'''N''' | ||
| + | |[[Datei:EN-US.png]] none | ||
| + | | colspan="2" |<p>No substitution occurred or is permitted.</p> | ||
|} | |} | ||